FDA Accepts Supplement for Furosemide by Epic Pharma
The FDA has accepted a supplemental application for Furosemide submitted by Epic Pharma.
Published: July 22, 2026
Updated: July 22, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Diuretic
Company: Epic Pharma
Asset: Furosemide
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Epic Pharma
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the supplemental application for Furosemide by Epic Pharma is significant as it may strengthen their competitive position in the cardiovascular and diuretic markets. Portfolio teams should assess the implications for market dynamics and potential shifts in share.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for the FDA's review process and any subsequent approval outcomes.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.